RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

Benzinga Newsdesk www.benzinga.com Positive 94.7%

Neg 0% Neu 0% Pos 94.7%

RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.